These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 22057933

  • 41. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J, Aparicio LS, Waisman GD.
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [Abstract] [Full Text] [Related]

  • 42. [Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances].
    Kato H, Kobayashi K, Uchida S.
    Nihon Rinsho; 2012 Sep; 70(9):1536-41. PubMed ID: 23012800
    [Abstract] [Full Text] [Related]

  • 43. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 44. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallée M, Savoie M, Perreault S, Laurin LP, Pichette V, Lafrance JP.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2136-42. PubMed ID: 26576619
    [Abstract] [Full Text] [Related]

  • 45. Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors.
    Ren H, Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Collister D, Tangri N.
    Clin Kidney J; 2022 Sep 07; 15(9):1713-1719. PubMed ID: 36003673
    [Abstract] [Full Text] [Related]

  • 46. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.
    Hagan AE, Farrington CA, Wall GC, Belz MM.
    Clin Nephrol; 2016 Jan 07; 85(1):38-43. PubMed ID: 26587776
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

  • 50. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C, Nassar T, Qunibi W.
    Expert Opin Pharmacother; 2021 Jan 12; 22(1):19-28. PubMed ID: 32892634
    [Abstract] [Full Text] [Related]

  • 51. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.
    Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G.
    J Nephrol; 2019 Aug 12; 32(4):499-516. PubMed ID: 31119681
    [Abstract] [Full Text] [Related]

  • 52. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J, Caballero R, Delpón E.
    Cardiovasc Drugs Ther; 2018 Feb 12; 32(1):99-119. PubMed ID: 29372448
    [Abstract] [Full Text] [Related]

  • 53. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e012655. PubMed ID: 31711387
    [Abstract] [Full Text] [Related]

  • 54. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
    Dong L, Xu W, Deng Y, Tan J, Qin W.
    Eur J Pharmacol; 2022 Sep 15; 931():175174. PubMed ID: 35964658
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Treatment of Hyperkalemia in Heart Failure.
    DeFilippis EM, Desai AS.
    Curr Heart Fail Rep; 2017 Aug 15; 14(4):266-274. PubMed ID: 28656517
    [Abstract] [Full Text] [Related]

  • 57. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.
    JAMA Intern Med; 2014 Mar 15; 174(3):347-54. PubMed ID: 24343093
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, Khoshniat-Rad F, Sood MM, Zheng S, Pravoverov L, Nesrallah GE, Garg AX, Go AS.
    Circ Cardiovasc Qual Outcomes; 2020 Sep 15; 13(9):e006415. PubMed ID: 32873054
    [Abstract] [Full Text] [Related]

  • 60. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, Garay A, Moliner P, Corbella M, Jovells-Vaqué S, Alcoberro L, Pons-Riverola A, Ramos-Polo R, Morillas H, Gómez-Hospital JA, Comin-Colet J.
    Eur J Intern Med; 2024 Jul 15; 125():89-97. PubMed ID: 38548513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.